Related Experiment Video
Updated: Sep 18, 2025
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Advances in hepatic arterial perfusion chemotherapy for hepatic metastases
Haodi Ou1,2, Xiaodong Li1,2, Shulin Chang1,2
1Department of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Abdominal Medicine Imaging, Jinan, China.
Hepatic arterial infusion chemotherapy (HAIC) is one of the local treatment modalities employed for liver metastases. HAIC targets the delivery of chemotherapy drugs to the affected area by inserting a catheter into the tumor's blood-supplying artery. This approach not only enhances drug concentration within the tumor site, but also significantly reduces systemic side effects. Currently, there are various chemotherapeutic regimens available for HAIC in liver metastases; however, determining the optimal therapeutic agent remains elusive. This article provides a comprehensive review of HAIC dosing regimens and multimodal therapy for liver metastases originating from colorectal, breast, and gastric cancers. Meanwhile, this paper briefly outlines ongoing research on HAIC treatment for liver metastases associated with esophageal cancer, gastroenteropancreatic neuroendocrine tumors, and uveal melanoma.
Hepatic arterial infusion chemotherapy (HAIC) is one of the local treatment modalities employed for liver metastases. HAIC targets the delivery of chemotherapy drugs to the affected area by inserting a catheter into the tumor's blood-supplying artery. This approach not only enhances drug concentration within the tumor site, but also significantly reduces systemic side effects. Currently, there are various chemotherapeutic regimens available for HAIC in liver metastases; however, determining the optimal therapeutic agent remains elusive. This article provides a comprehensive review of HAIC dosing regimens and multimodal therapy for liver metastases originating from colorectal, breast, and gastric cancers. Meanwhile, this paper briefly outlines ongoing research on HAIC treatment for liver metastases associated with esophageal cancer, gastroenteropancreatic neuroendocrine tumors, and uveal melanoma.
